Blood-brain interfaces: relevance to cerebral drug metabolism
- PMID: 8597122
- DOI: 10.1016/0378-4274(95)03510-9
Blood-brain interfaces: relevance to cerebral drug metabolism
Abstract
The brain, with the exception of the circumventricular organs (CVOs), is partially protected from the invasion of blood-borne chemicals by the tight junctions that link adjacent cerebral endothelial cells and form the structural basis of the blood-brain barrier (BBB). In addition to the BBB, the epithelial layer of the choroid plexuses and the barrier layer of the arachnoid membrane complex comprise a second system for protecting the brain, a system often referred to as the blood-cerebrospinal fluid (CSF) barrier. In the past several years, several enzymes that are involved in hepatic drug metabolism have been found in the small microvessels from brain, the choroid plexuses, and the leptomeninges (pia plus arachnoid mater) as well as in some CVOs. These drug-metabolizing systems are inducible and may act at these various interfaces as 'enzymatic barriers' to influx. In particular, the activities of these enzymes in choroidal tissue are so high that the choroid plexuses can well be the major site of drug metabolism in the brain. The fate of intracerebrally formed polar metabolites and the potential of the blood-brain and blood-CSF barriers as sites for metabolic activation-induced neurotoxicity are discussed.
Similar articles
-
Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs.J Neurochem. 1994 Mar;62(3):1089-96. doi: 10.1046/j.1471-4159.1994.62031089.x. J Neurochem. 1994. PMID: 8113796
-
Contributions of Drug Transporters to Blood-Brain Barriers.Adv Exp Med Biol. 2019;1141:407-466. doi: 10.1007/978-981-13-7647-4_9. Adv Exp Med Biol. 2019. PMID: 31571171 Review.
-
Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules.Mol Pharm. 2013 May 6;10(5):1473-91. doi: 10.1021/mp300518e. Epub 2013 Jan 23. Mol Pharm. 2013. PMID: 23298398 Review.
-
The development of the human blood-brain and blood-CSF barriers.Neuropathol Appl Neurobiol. 1986 Jul-Aug;12(4):337-58. doi: 10.1111/j.1365-2990.1986.tb00146.x. Neuropathol Appl Neurobiol. 1986. PMID: 3534622 Review.
-
Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain.Cell Mol Biol (Noisy-le-grand). 1999 Feb;45(1):15-23. Cell Mol Biol (Noisy-le-grand). 1999. PMID: 10099836 Review.
Cited by
-
Modification in CSF specific gravity in acutely decompensated cirrhosis and acute on chronic liver failure independent of encephalopathy, evidences for an early blood-CSF barrier dysfunction in cirrhosis.Metab Brain Dis. 2017 Apr;32(2):369-376. doi: 10.1007/s11011-016-9916-9. Epub 2016 Oct 11. Metab Brain Dis. 2017. PMID: 27730496
-
Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Clin Pharmacokinet. 2013 Jul;52(7):511-42. doi: 10.1007/s40262-013-0062-9. Clin Pharmacokinet. 2013. PMID: 23605634 Review.
-
In vivo methods to study uptake of nanoparticles into the brain.Pharm Res. 2011 Mar;28(3):456-71. doi: 10.1007/s11095-010-0291-7. Epub 2010 Oct 7. Pharm Res. 2011. PMID: 20924653 Free PMC article. Review.
-
Neurovascular Drug Biotransformation Machinery in Focal Human Epilepsies: Brain CYP3A4 Correlates with Seizure Frequency and Antiepileptic Drug Therapy.Mol Neurobiol. 2019 Dec;56(12):8392-8407. doi: 10.1007/s12035-019-01673-y. Epub 2019 Jun 26. Mol Neurobiol. 2019. PMID: 31243719 Free PMC article.
-
Effect of status epilepticus and antiepileptic drugs on CYP2E1 brain expression.Neuroscience. 2014 Dec 5;281:124-34. doi: 10.1016/j.neuroscience.2014.09.055. Epub 2014 Oct 2. Neuroscience. 2014. PMID: 25280786 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous